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Summary 
Stahle transfected human T-celllines expressing anti-
sense HIV-1 gag or tat RNAs were tested for their 
resistance against HIV -1 infection. Quantitative ana-
lyzes of p24 and viral RNA expression did not detect 
any differences between antisense-RNA expressing 
and control cell lines. The failure of an antisense 
inhibitory effect might be due to the observed ceassa-
tion of the antisense RNA-transcription in HIV-1 
infected cells. 
The Iack of successful treatment of HIV-induced 
AIDS justify attempts to explore feasibility of gene 
therapeutic procedures. One of the discussed regimes 
is the transplantation of bone marrow cells which 
have been rendered resistant to HIV infection. The 
unresolved problern is how to achieve and maintain 
the HIV resistance. Genetically manipulated cells ex-
pressing HIV antisense RNA could theoretically be 
used for this purpose. The first suggestion for thera-
peutic use of antisense oligonucleotides was in papers 
from Zamecnik's laboratory. They demonstrated an 
inhibitory effect of complementary oligodeoxynu-
cleotides on Raus sarcoma virus replication (Zamec-
nik and Stephenson, 1978). An important modifica-
tion of this technology was introduced by Izant and 
Weintraub (1984). They used antisense-RNA express-
ing vectors which, when integrated into the hast ge-
nome, constantly supply the cell with antisense RNA. 
Subsequently, similar approaches have been used suc-
cessfully to inhibit expression of several cellular and 
viral genes. 
To inhibit HIV replication, thus far only attempts 
have been using synthetic oligonucleotides (Agraval et 
· al., 1988; Zaia et al., 1988; Shibahara et al., 1989). The 
problern of this approach are in a requirement for a 
continuous treatment of cells with high concentra-
tions of antisense oligonucleotides and their cytotox-
icity. Here we have examined the use of antisense-
RNA expressing vectors to prevent HIV infection of 
human T -cells. 
HIV -1 tat and gag genes were chosen for construction 
of the antisense vectors from following reasons. They 
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represent relatively more stable parts of the HIV ge-
nome (Starcich et al., 1986) and thus the efficiency of 
their antisense transcripts should be less dependent on 
the sequence variability of an infecting virus. Furth-
ermore, since gag and tat gene products are essential 
at the early stages of the virus replication, suppression 
of their cellular concentration by the antisense RNA 
should be an effective way to inhibit the virus produc-
tion. 
Human CMV enhancer/promoter, which is known as 
one of the strongest promoter sequences (Boshart et 
al., 1985), was cloned in front of reversed HIV-1 gag 
and tat sequences (Arya et al., 1985; Fisher et al., 
1985) to generate the recombinant vectors pgagRneo 
and ptatRneo (Figure 1). Linearized DNA of these 
constructs was transfected into H9 and Jurkat cells. 
Neomycin resistant cell clones were recloned and the 
presence of the integrated transgenewas confirmed by 
Southern-blot hybridization. Celllines with no appar-
ent DNA rearrangement were selected and screened 
for the expression of antisense RNA. Northern-blot 
hybridizations revealed several cell lines positively 
hybridizing with gag or tat probes. The exact nature of 
the hybridizing RNA was proved by SI nuclease 
mapping. This analysis confirmed that these RNAs 
represent the expected antisense transcripts. The two 
bands seen in Figure 1 correspond to two differently 
spliced antisense gag RNAs. 
P 1 6 ISV40 t int. + polyA hCMV Kp24 gag : 
,-------, ,.----------,SV40 t int. + polyA 
hCMV Krevtat +-1-----
Figure 1: HIV-1 antisense constructs 
In order to assess a potential antiviral effect of the 
antisense RNAs, cells were infected with HIV-1 
(m.o.i. 0.01) and the course ofthe infection was moni-
tared by cell viability counting. These observations 
indicated a slightly delayed progression of the viral 
infection in some celllines (data not shown). How-
ever, in order to evaluate quantitatively the effect of 
the antisense RN A on the HIV -1 replication two prob-
lems had tobe encountered. Firstly, the expression of 
the CD4 receptor varies among different cell1ines and 
thus may affect their susceptibility to HIV infection. 
Therefore, only the cell lines with comparab1e CD4 
receptor expression were used for further studies. Se-
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Table 1: Expression ofp24 in ce/ls infected with HJV-1 or HIV-2 
a) b) c) 
cell line antisense RNA CD4 (%) 
HB-6-1 26.8 
HB-4-5 86.5 
HB-2-1 gag ++ 23.9 
HB-1-6 gag +++ 71.1 
JB-5-5 6.9 
JC-1 22.7 
JA-3-2 tat ++ 10.1 
JA-2-6 tat + 10.2 
JA-9-0 tat + 12.3 
p24 (ng/ml) d) 
HIV-1 HIV-2 
7.5 0.15 
11.3 0.19 
9.3 0.16 
10.0 0.19 
1.4 0.03 
4.6 0.08 
0.8 0.02 
2.5 0.04 
2.0 0.05 
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ratio p24 
HIV-1/HIV-2 
50.0 
59.5 
58.1 
52.6 
46.6 
57.5 
40.0 
62.5 
40.0 
a) The celllines derived from the H9 or Jurkat cells are marked with capital H or J, respectively. 
b) Relativeexpression of antisense RNAs was estimated by Northern-blot hybridization. 
c) CD4 receptor expression is indicated as% of positive cells stained by a FITC-anti-CD4 antibody analyzed by FACS. 
d) p24 expression in HIV-1 or HIV-2 infected cells (m.o.i. 0.01) was determinded 3 days p.i. using a HIV-1 p24 ELISA kit (DuPont). 
cond1y, there are inherent differences among different 
celllines to support virus replication. Forthis reason 
replica plates were infected with HIV-1 or with HIV-2 
and their p24 expression was measured in an ELISA 
test. Due to considerable sequence differences (Zag-
ury et al., 1988), HIV-2 replication should not be 
affected by the HIV -1 antisense RNA and thus its p24 
expression served as an internal control. The results 
presented in Table 1 do not show any significant 
differences in HIV-1 p24 expression between antisen-
se-RNA expressing and control cells. 
To confirm the data, we analyzed the expression of 
viral sense-and transgene antisense-RNAs directly in 
cells infected with HIV-1 with a probe capable of 
detecting both types of transcripts. Our preliminary 
data indicate that relatively high Ievels of antisense 
transcripts are present in uninfected cells, but their 
amount decreases after HIV-1 infection concomit-
antly with increasing viral transcription. Thus it is an 
additional evidence that despite of the high ratio of 
antisense to sense-RNA made in early stages of infec-
tion, the HIV -1 replication was not significantly af-
fected. 
Several reasons might account for the failure of an 
antisense effect. A general switch off of cellular trans-
cription is excluded, since the transcription of other 
cellular geneswas not affected by the HIV -1 infection. 
It seems more likely that a competition for common 
transcription factors (Nabel and Baltimore, 1987) to-
gether with a compartmentalization ofviral transcrip-
tion provides a decisive advantage for HIV-1 replica-
tion. 
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